Éva B.
- Country
- Hungary
- Department
- Reumatológia
Research Overview
- Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
Data & Insights
Has run more than one trial at 295 of 490 partner sites.
Specializations
Inflammatory Arthritis
Specializes in investigating novel treatments for rheumatoid arthritis, with particular focus on biological disease-modifying antirheumatic drugs and innovative combination therapies.
- Advanced therapy development
- Biosimilar evaluation
- Long-term treatment outcomes
Extensive experience in assessing both established and emerging therapeutic approaches for inflammatory joint conditions.
Psoriatic Disease
Conducts research in psoriatic arthritis and plaque psoriasis, focusing on innovative biological therapies and their effectiveness in treating multiple disease manifestations.
- Biologic-naive patient treatments
- Axial disease management
- Novel therapeutic compounds
Investigates targeted treatments for both skin and joint manifestations of psoriatic disease.
Autoimmune Conditions
Specializes in researching treatments for Sjögren's Syndrome and axial spondyloarthritis, with emphasis on systemic disease manifestations and innovative therapeutic approaches.
- Systemic disease management
- Novel immunomodulatory therapies
- Long-term safety evaluation
Focuses on addressing both localized and systemic manifestations of autoimmune conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.